Casodex and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Casodex (bicalutamide), especially for people who are male, 60+ old, also take Zometa, and have Metastases to bone.

The phase IV clinical study analyzes which people have Hearing loss when taking Casodex. It is created by eHealthMe based on reports of 10,594 people who have side effects when taking Casodex from the FDA, and is updated regularly.

What is Casodex?

Casodex has active ingredients of bicalutamide. It is often used in prostate cancer. eHealthMe is studying from 10,725 Casodex users. Check the latest studies of Casodex.

What is Hearing loss?

Hearing loss is found to be associated with 1,357 drugs and 2,387 conditions by eHealthMe. Check the latest studies of Hearing loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 12, 2026

10,594 people reported to have side effects when taking Casodex.
Among them, 127 people (1.2%) have Hearing loss.

Among these 127 people:

* Approximation only. Some reports may have incomplete information.

Do you take Casodex and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Casodex:

Casodex (10,725 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

How severe was Hearing loss and when was it recovered:

Hearing loss in Casodex

Expand to all the drugs that have ingredients of bicalutamide:

Hearing loss and drugs with ingredients of bicalutamide (136 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Casodex:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,357 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,387 conditions)

Related publications that referenced our studies

Peng, C. C., Chen, C. Y., Chen, C. R., Chen, C. J., Shen, K. H., Chen, K. C., & Peng, R. Y., "Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model", Scientific reports, 2018 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Peng, C. C., Chen, C. Y., Chen, C. R., Chen, C. J., Shen, K. H., Chen, K. C., & Peng, R. Y., "Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model", Scientific reports, 2018 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on bicalutamide (the active ingredients of Casodex) and Casodex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.